Jane Street
ALLO icon

Jane Street’s Allogene Therapeutics ALLO Stock Holding History

Jane Street’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-505,273
Closed -$1.11M – 11436
2026
Q1 		$1.23M Sell
505,273
-1,655,110
-77% -$3.32M ﹤0.01% 6061
2025
Q4 		$2.96M Buy
2,160,383
+944,610
+78% +$1.25M ﹤0.01% 4060
2025
Q3 		$1.51M Buy
1,215,773
+803,143
+195% +$958K ﹤0.01% 5454
2025
Q2 		$466K Sell
412,630
-704,051
-63% -$936K ﹤0.01% 7054
2025
Q1 		$1.63M Buy
1,116,681
+952,158
+579% +$1.8M ﹤0.01% 4694
2024
Q4 		$350K Sell
164,523
-273,198
-62% -$674K ﹤0.01% 7479
2024
Q3 		$1.23M Sell
437,721
-167,416
-28% -$446K ﹤0.01% 5470
2024
Q2 		$1.41M Buy
605,137
+507,464
+520% +$1.5M ﹤0.01% 5115
2024
Q1 		$437K Sell
97,673
-259,256
-73% -$1.08M ﹤0.01% 6918
2023
Q4 		$1.15M Buy
356,929
+330,276
+1,239% +$937K ﹤0.01% 5323
2023
Q3 		$84.5K Sell
26,653
-86,250
-76% -$378K ﹤0.01% 8023
2023
Q2 		$561K Buy
112,903
+52,502
+87% +$284K ﹤0.01% 6138
2023
Q1 		$298K Buy
60,401
+50,307
+498% +$323K ﹤0.01% 7206
2022
Q4 		$63.5K Sell
10,094
-154,913
-94% -$1.43M ﹤0.01% 8284
2022
Q3 		$1.78M Buy
165,007
+80,706
+96% +$1.1M ﹤0.01% 4386
2022
Q2 		$961K Buy
84,301
+55,936
+197% +$497K ﹤0.01% 5552
2022
Q1 		$259K Sell
28,365
-38,748
-58% -$404K ﹤0.01% 8612
2021
Q4 		$1M Buy
67,113
+51,759
+337% +$913K ﹤0.01% 5888
2021
Q3 		$395K Buy
+15,354
New +$365K ﹤0.01% 7697
2021
Q2 		– Sell
-11,895
Closed -$339K – 9710
2021
Q1 		$420K Sell
11,895
-17,963
-60% -$606K ﹤0.01% 7104
2020
Q4 		$753K Sell
29,858
-119
-0.4% -$3.88K ﹤0.01% 5117
2020
Q3 		$1.13M Buy
29,977
+8,872
+42% +$334K ﹤0.01% 3897
2020
Q2 		$904K Buy
+21,105
New +$763K ﹤0.01% 4207
2019
Q4 		– Sell
-27,295
Closed -$744K – 5006
2019
Q3 		$744K Buy
+27,295
New +$777K ﹤0.01% 2989

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street's ALLO Position: Q2 2026 in Review

Jane Street sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 505,273 shares — an estimated $1.11M sold.

Jane Street first reported a position in ALLO in Q3 2019 and held it in 24 quarters. The position peaked at $2.96M in Q4 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Jane Street reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 505,273 Allogene Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Jane Street first reported a position in Allogene Therapeutics in Q3 2019 and held it in 24 quarters.
  • Jane Street's Allogene Therapeutics position peaked at $2.96M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.